COMMUNIQUÉS West-GlobeNewswire

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
03/06/2025
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment period Favorable safety and tolerability, particularly when compared to [...]
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
03/06/2025
Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid [...]
Merus N.V. Announces Proposed Public Offering of Common Shares
03/06/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific [...]
Windtree Announces Plan for Cryptocurrency Treasury Policy
03/06/2025
Windtree intends to accept cryptocurrency as an option for payment and also to hold as an asset WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: [...]
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results
03/06/2025
Highlights of the first quarter include: Revenue of $330.8 million, an increase of 15% compared to $287.6 million in Q1 FY25. Net income of $53.9 million, an increase of 87% compared to $28.8 million in Q1 FY25, with [...]
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
03/06/2025
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met primary endpoint with a complete response (CR) rate [...]
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
03/06/2025
Biofrontera received patent approval for the revised formulation of Ameluz ® in April 2025, extending patent protection through to December 2043. The Orange Book is published by the U.S. Food and Drug Administration ( [...]
EssilorLuxottica: successful Euro 1 billion bond issuance
03/06/2025
NOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR [...]
EssilorLuxottica : Succès du placement d'une émission obligataire d’un montant d’1 milliard d'euros
03/06/2025
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMÉRIQUE, AU CANADA, EN AUSTRALIE, AU JAPON, EN AFRIQUE DU SUD OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE IL SERAIT ILLÉGAL DE LE [...]
RESTEM to Present at the 2025 BIO International Convention
03/06/2025
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres [...]
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
03/06/2025
New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years 1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in standard and high- [...]
New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma
03/06/2025
Sustained MRD negativity (10 -5 ) rates at 24 months or longer were more than doubled in transplant eligible patients treated with daratumumab-VRd vs VRd alone in the Phase 3 PERSEUS study 1 Data from the Phase 3 [...]
Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
03/06/2025
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms 1 Data show a nearly 50 percent reduction in disease progression in [...]
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
03/06/2025
Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE [...]
Vital Wound Care Launches AI-Driven Wound App and Expands In-Home Services Across Greater Houston
03/06/2025
New AI-powered app and biologic wound therapies bring hospital-grade care to homes across Greater Houston. Image by Vital Wound Care HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- On May 1, Vital Wound Care introduced a [...]
Epilepsy Foundation of America Awards $250,000 at 13th Annual Shark Tank Competition
03/06/2025
Janine Erler, winner of the 2025 Investment Prize for Neumirna Therapeutics. Presenting the prize is Bernice Martin Lee, Epilepsy Foundation of America’s (EFA) Chief Executive Officer; Jacqueline French, MD, EFA’s [...]
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
03/06/2025
Result of the payment of dividends in shares and record of the corresponding capital increase Paris, France (June 3, 2025 – 4:30 pm) – The Annual General Meeting of EssilorLuxottica has decided to grant to the [...]

Pages